MV-003 Dysbiosis

Indicaton

Dysbiosis

ApyraMed promotes microbiome recovery and selection of beneficial bacteria after antibiotic treatment. This results in powerful control of antibiotic-induced enteric infections and metabolic alterations.

Therapeutic indications

Type of product

Other biologics

Table

Phase

Discovery
Partnering status

Not partnered
Available in

World-Wide

You may also be interested in

Regkirona (regdanvimab)

Regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19

Marketed

3D CoSeedis in chip Assays

Preclinical 3D Study models for oncology and neurology.

Marketed

Cadazolid

Crohn's disease

Phase II started